RemeGen Co., Ltd. REGMF
9.96 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
10.73 Day range 10.93
9.54 52-week range 12.85
- YTD
- +1.53%
- 1 year
- -9.45%
- Market cap
- 5.62B
- EPS (ttm)
- 1.49
- P/E ratio
- 6.68
- YTD return
- +1.53%
- 1-year return
- -9.45%
- Volume
- 400
- Avg volume
- 47
- Open
- 10.73
- Previous close
- 9.96
- Day's range
- 10.73 – 10.93
- 52-week range
- 9.54 – 12.85
YTD +0.15 (+1.53%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 28, 2026 | Mar 31, 2026 | — | 0.08406 | — | — |
| Feb 28, 2026 | Dec 31, 2025 | — | 0.3245 | — | — |
| Oct 30, 2025 | Sep 30, 2025 | — | -0.02528 | — | — |
| Aug 22, 2025 | Jun 30, 2025 | — | -0.0516 | — | — |
| Apr 28, 2025 | Mar 31, 2025 | — | -0.06337 | — | — |
News
AbbVie, RemeGen partner on experimental solid tumor treatment 
Short Interest in RemeGen Co., Ltd. (OTCMKTS:REGMF) Drops By 45.0% 
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries 
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA 
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement 
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis 
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China 
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
Your note
Sign in to keep a note on REGMF — it syncs with the Stock Master app.